Table 2. Prevalence of chronic cough in respiratory disease.
| Disease | Study | Prevalence in disease |
|---|---|---|
| Asthma | Çolak et al., CGPS. Cross-sectional population study (n=14,740). 6% had asthma, Denmark (7) | 8% reported CC |
| Osman et al., observational study of moderate-severe asthma in clinic (n=162), UK (28) | 58% reported cough in last week. 12% reported cough as dominant symptom of concern | |
| de Marco et al., observational study of community asthmatics (n=856), UK (29) | 30% reported CC | |
| Morjaria et al., post-hoc analysis prospective study uncontrolled asthma (n=1,701), UK (30) | Cough reported on median 323 days/year. Cough predominant in females and high BMI |
|
| COPD | Landt et al., 2020, CGPS. Cross-sectional population study (n=43,271). 19% had COPD, Denmark (6) | 10% reported CC |
| Agusti et al, 2010, observational, longitudinal, controlled study of stable COPD patients (n=2,164), Spain (31) | Chronic bronchitis in 35% | |
| Kim et al., 2011, COPDGene observational study, stable COPD (n=1,061), USA (32) | Chronic bronchitis in 27% | |
| Burgel et al., 2009, cross-sectional multicentre study, stable COPD (n=433), France (33) | Chronic bronchitis in 74% | |
| Mejza et al., 2017, observational data (n=24,855), 33 international centres (34) | Prevalence of chronic bronchitis in population: range (0–10.8%). 10.8% in Lexington (USA); 0% in Ile-Ife (Nigeria) and Blantyre (Malawi) | |
| Bronchiectasis | Pasteur et al., 2010. BTS guidelines, UK (35) | >90% have chronic productive cough |
| Özgün Niksarlioglu et al., 2016, stable bronchiectasis (n=133), Turkey (36) | 82% reported cough | |
| King et al., 2006, newly presenting bronchiectasis (n=103), Australia (37) | 98% reported CC | |
| IPF | Ryerson et al., 2011, registry of IPF (n=242), USA (8) | 84.3% reported cough |
| Guenther et al., 2018, baseline registry data in IPF (n=525), Europe (38) | 53.2% reported dry cough at presentation | |
| Behr et al., 2015, consecutive IPF patients (n=502), Germany (39) | 74.7% reported current cough | |
| Glaspole et al., 2017, registry of IPF patients (n=516), Australia (40) | 88.5% reported cough | |
| Cheng et al., 2017, consecutive IPF (n=77), Australia (41) | 87% reported cough | |
| Lan et al., 2020, survey (n=53), Australia (42) | 81% reported cough | |
| Other-ILD | Guenther et al., 2018, baseline registry data in other-ILD (n=561), Europe (38) | 50.2% reported dry cough at presentation |
| Cheng et al., 2017, consecutive SSc-ILD (n=67), Australia (41) | 68% reported cough | |
| Cheng et al., 2017, consecutive CHP (n=32), Australia (41) | 83% reported cough | |
| Lan et al., 2020, survey of ILD, 30% IPF (n=179), Australia (42) | 72% reported cough; 66% of CTD-ILD; 71% of NSIP | |
| Tashkin et al., 2017, SSc-ILD enrolled in SLS2 (n=142), USA (43) | 61.3% reported frequent cough | |
| Theodore et al., 2012, SSc-ILD enrolled in SLS1 (n=156), USA (44) | 73% reported cough | |
| Sarcoidosis | Sinha et al., 2016, consecutive sarcoidosis (n=32), UK (4) | 56% reported CC |
| Pietinalho et al., 1996, consecutive sarcoidosis in Mjölbolsta, Finland (n=573), and Sapporo, Japan (n=467) (45) | Mjölbolsta: 33% reported cough; Sapporo: 3% reported cough | |
| Nardi et al., 2011, retrospective cohort stage IV sarcoidosis, n=142, France (46) | 51.4% reported cough | |
| Kovacova et al., 2019, retrospective cohort (n=101), Slovakia (47) | 64% reported cough | |
| Al-Khouzaie et al., 2011, retrospective cohort (n=33), Saudi Arabia (48) | 54% reported cough |
CGPS, Copenhagen General Population Study; CC, chronic cough; BMI, body mass index; COPD, chronic obstructive pulmonary disease; BTS, British Thoracic Society; IPF, idiopathic pulmonary fibrosis; ILD, interstitial lung disease; SSc, systemic sclerosis; CHP, chronic hypersensitivity pneumonitis; CTD, connective tissue disease; NSIP, nonspecific interstitial pneumonia; SLS, scleroderma lung study.